SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-050307
Filing Date
2024-04-23
Accepted
2024-04-23 07:00:47
Documents
17
Period of Report
2024-04-23
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2412300d2_8k.htm   iXBRL 8-K 32588
2 EXHIBIT 99.1 tm2412300d2_ex99-1.htm EX-99.1 16723
3 GRAPHIC image_001.jpg GRAPHIC 3983
4 GRAPHIC image_002.jpg GRAPHIC 3983
5 GRAPHIC image_003.jpg GRAPHIC 3983
  Complete submission text file 0001104659-24-050307.txt   247549

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA syn-20240423.xsd EX-101.SCH 3042
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20240423_lab.xml EX-101.LAB 34240
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20240423_pre.xml EX-101.PRE 22378
20 EXTRACTED XBRL INSTANCE DOCUMENT tm2412300d2_8k_htm.xml XML 3692
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 24862661
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)